Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9934859 | 0.75 | GAA (0.48) | MAPTGAA | |
| SCHEMBL30082351 | 0.75 | GAA (0.48) | MAPTGAA | |
| SCHEMBL3113175 | 0.75 | GAA (0.48) | MAPTGAA | |
| SCHEMBL1505206 | 0.75 | GAA (0.48) | MAPTGAA | |
| SCHEMBL31695999 | 0.75 | GAA (0.48) | MAPTGAA | |
| SCHEMBL8119025 | 0.75 | GAA (0.48) | MAPTGAA | |
| SCHEMBL8554754 | 0.75 | GAA (0.48) | MAPTGAA | |
| SCHEMBL3241604 | 0.75 | MAPT (0.48) | MAPTGAAP2RX4RAB9ASMN1; SMN2 | |
| SCHEMBL11428738 | 0.75 | GAA (0.48) | MAPTGAA | |
| SCHEMBL8799466 | 0.75 | GAA (0.43) | MAPTGAAP2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4663454-A | Process to prepare α-chloroalprazolam | THE UPJOHN COMPANY (US) | 1987-05-05 | — | — | US | claimed |
| CN-104684981-B | For producing the polycarbonate compositions of the optical quality product with high-quality and good workability | 沙特基础全球技术有限公司 | 2016-10-19 | — | — | CN | disclosed |
| US-9023818-B2 | Pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use | GLYCON LLC (US) | 2015-05-05 | — | — | US | disclosed |
| US-20140057869-A9 | Novel Pharmaceutical Agents Containing Carbohydrate Moieties And Methods Of Their Preparation And Use | IMI INTERNATIONAL MEDICAL INNOVATIONS, INC. | 2014-02-27 | — | — | US | disclosed |
| US-20110237544-A1 | Novel Pharmaceutical Agents Containing Carbohydrate Moieties And Methods Of Their Preparation And Use | CHRISTIAN SAMUEL T | 2011-09-29 | — | — | US | disclosed |
| US-20090062256-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-05 | — | — | US | disclosed |
| US-7456278-B2 | Lactams substituted by cyclic succinates as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080103128-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-05-01 | — | — | US | disclosed |
| US-7354914-B2 | Lactams substituted by cyclic succinates as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
| US-20060189547-A1 | Novel pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use | CHRISTIAN SAMUEL T | 2006-08-24 | — | — | US | disclosed |
| CN-1128264-A | Crystalline form of dihydro-2,3-benzodiazepine derivative | LILLY CO ELI (US) | 1996-08-07 | — | — | CN | disclosed |
| EP-0597540-B1 | Aryl-fused and hetaryl-fused-2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC (US) | 1996-06-05 | — | — | EP | disclosed |
| CN-1123282-A | Stereoselective process for producing dihydro-2,3-benzodiazepine derivatives | LILLY CO ELI (US) | 1996-05-29 | — | — | CN | disclosed |
| CN-1122338-A | Physical form of dihydro-2,3-benzodiazepine derivative | LILLY CO ELI (US) | 1996-05-15 | — | — | CN | disclosed |
| WO-1996006606-A1 | DIHYDRO-2,3-BENZODIAZEPINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1996-03-07 | — | — | WO | disclosed |
| EP-0699676-A1 | Physical form of dihidro-2,3-benzodiazepine derivative | ELI LILLY AND COMPANY (US) | 1996-03-06 | — | — | EP | disclosed |
| EP-0699677-A1 | Stereoselective process for producing dihydro-2,3-benzodiazepine derivatives | ELI LILLY AND COMPANY (US) | 1996-03-06 | — | — | EP | disclosed |
| US-5380721-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0597540-A1 | Aryl-fused and hetaryl-fused-2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1994-05-18 | — | — | EP | disclosed |
| EP-0475527-A2 | Aryl-fused and hetaryl-fused-2, 4-diazepine and 2, 4-diazocine antiarrhythmic agents | STERLING DRUG INC. (US) | 1992-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189547-A1 | Novel pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use | CSGALNACT1, DDOST, STT3B | MAPT 90/4885GAA 184/4885P2RX4 2421/4885 |
| US-20090062256-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BACE1, APP, APH1A | MAPT 47/4885GAA 253/4885P2RX4 4248/4885 |
| US-20080103128-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION | APH1A, APH1B, APP | MAPT 105/4885GAA 115/4885P2RX4 4170/4885 |
| US-20110237544-A1 | Novel Pharmaceutical Agents Containing Carbohydrate Moieties And Methods Of Their Preparation And Use | CSGALNACT1, DDOST, STT3B | MAPT 90/4885GAA 184/4885P2RX4 2421/4885 |
| US-20140057869-A9 | Novel Pharmaceutical Agents Containing Carbohydrate Moieties And Methods Of Their Preparation And Use | CSGALNACT1, DDOST, STT3B | MAPT 90/4885GAA 184/4885P2RX4 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.